1st Jul 2020 13:10
ValiRx PLC - London-based clinical stage biotechnology company - Pretax loss narrowed in 2019 to GBP2.7 million from GBP4.8 million. Research and development costs down 42% to GBP984,457, and administrative expenses trimmed 14% to GBP1.9 million. Like in 2018, ValiRx generated no revenue.
Current stock price: 7.29 pence
Year-to-date change: down 51%
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ValiRx